<p><strong>Pediatric Use:&nbsp;</strong>Use in patients under 18 years of age is not recommended. Safety and effectiveness in pediatric patients below the age of 18 years have not been established.<br />
<br />
<strong>Geriatric use</strong>: Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone. This risk is further increased in patients receiving concomitant corticosteroid therapy.<br />
<br />
<strong>Renal Impairment</strong>: Closely monitor serum creatinine levels in patients with severe renal impairment (eGFR 15 29 mL/min/1.73 m2 ) receiving intravenous delafloxacin. If serum creatinine level increases occur, consider changing to oral delafloxacin. Discontinue Delafloxacin if eGFR decreases to &lt;15 mL/min/1.73 m2.<br />
<br />
<strong>Hepatic Impairment</strong>: No dosage adjustment is necessary for Delafloxacin in patients with hepatic impairment</p>